Q2-osavuosiraportti
70 päivää sitten‧34 min
Tarjoustasot
Spotlight Stock Market SE
Määrä
Osto
3 790
Myynti
Määrä
7 950
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 000 | SWB | NON | ||
| 7 000 | SWB | AVA | ||
| 12 353 | NON | AVA | ||
| 6 010 | NON | AVA | ||
| 3 187 | NON | AVA |
Ylin
0,628VWAP
Alin
0,597VaihtoMäärä
0,1 85 914
VWAP
Ylin
0,628Alin
0,597VaihtoMäärä
0,1 85 914
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordnet Bank AB | 44 766 | 26 511 | +18 255 | 18 411 |
| Swedbank AB | 15 100 | 0 | +15 100 | 0 |
| Carnegie Investment Bank AB | 6 205 | 0 | +6 205 | 0 |
| Nordea Bank Abp | 870 | 0 | +870 | 0 |
| Skandinaviska Enskilda Banken AB | 39 | 0 | +39 | 0 |
| SSW Market Making GmbH | 0 | 3 640 | −3 640 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Avanza Bank AB | 18 934 | 55 763 | −36 829 | 18 640 |
| SSW Market Making GmbH | 0 | 3 640 | −3 640 | 0 |
| Skandinaviska Enskilda Banken AB | 39 | 0 | +39 | 0 |
| Nordea Bank Abp | 870 | 0 | +870 | 0 |
| Carnegie Investment Bank AB | 6 205 | 0 | +6 205 | 0 |
| Swedbank AB | 15 100 | 0 | +15 100 | 0 |
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 14.11. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 19.8. | |
| 2024 Yhtiökokous | 12.5. | |
| 2025 Q1-osavuosiraportti | 8.5. | |
| 2024 Q4-osavuosiraportti | 21.2. | |
| Merkintäoikeusanti | 3.1. |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
14.10.·AcuCort AB: AcuCort strengthens its management team with the appointment of Anna Chérouvrier Hansson as Business Development Director today at 13:00 ∙ Cision AcuCort has appointed Anna Chérouvrier Hansson as its Business Development Director. The appointment is part of AcuCort's continued commercial development and focus on strengthening strategic partnerships to support the launch of Zeqmelit® in additional markets. Anna Chérouvrier Hansson has more than 15 years of experience in business development, sales and marketing within the life science sector. She has held senior positions in both listed companies and fast-growing SMEs, including SenzaGen and Camurus. At SenzaGen, she played a key role in building and driving the company's business development and commercialization strategy, establishing a global network of licensees and distributors, and negotiating international agreements. At Camurus, she was instrumental in launching the company’s first commercial product in supportive cancer care across multiple international markets. “We are very pleased to welcome Anna to AcuCort. Her solid experience in business development, international partnerships and commercialization in life science will be an important addition to our growth journey. Anna’s drive, structured approach and strategic skills make her an excellent fit for our team,” says Jonas Jönmark, CEO of AcuCort. “I am very much looking forward to becoming part of AcuCort and contributing to the company’s continued growth and commercial success,” says Anna Chérouvrier Hansson, newly appointed Business Development Director. For further information, please contact:
24.10.·It only applies that everyone who has different medications approves this film as an alternative.. I think it can help you and me as well as those who own shares...2 päivää sitten · Muokattu·Yes, this way of giving medicine is nothing less than revolutionary, and that is why I have them in my portfolio. The big problem is that Jonas Jönmark has refused to sell Zeqmelit to people with cancer and to people with allergies. I still don't understand that he is CEO, all other companies would have let him go a long time ago, already when he made an excuse that there was a year's delay in the launch because there was nonsense with the labels. Just for the record, I have worked in a medical company where I was responsible for the labels, and it has never taken a year to get new ones if there was nonsense with the first batch. If it was because there were problems with the text that had to be approved, then it is also amateurish that this was not cleared and in place. It is four years too late for Anna Chérouvrier Hansson to be hired, she should have been there from the start, so that there were no logistics problems. The CEO is a liability at AcuCort and therefore he must be replaced with someone who has experience in sales and management.- 8.10. · Muokattu·Strange and unfortunate that this has not been shared here on Shareville. I can see that it has been viewed 66 times. English is spoken and there are no texts that can translate the presentation. Acucort presentation September 24, 2025 https://vimeo.com/1121626529?&login=true#_=_
8.10.·I was at the conference - and it was a really good presentation - and bought it afterwards. But yes - I did some research - and among professionals there is great enthusiasm for the product and there is a really good dialogue that way - but the company seems to have big challenges with communication even with the end users!? I have written to the CEO to find out when and how we will see an intensified effort aimed at the users!? - 27.9.·I didn't know about AcuCort until I heard them at the weekly LifeSciences conference 24/9'2025 - it sounded so exciting that during the presentation I took a small position of 20,000 shares at 0.55 - and then thought that I would take a closer look at it, and then possibly add to it along the way in their commercialization journey. And then I had a chat with ChatGPT about the case - and 16 pages came out of it, which I have as a pdf in my FB Group "Dividend & Risk Stocks_Balanced Portfolio", if anyone is interested.
- 25.9.·Acucort receives SME status extension from EMA Life science company Acucort has received an extension of its SME status (small or medium-sized enterprises) from the European Medicines Agency (EMA) until the end of 2026, according to a press release. The extension means that the company will be fully or partially exempt from fees in connection with regulatory applications related to the sale and marketing of medicines within the EU and EEA. "It is of key importance to maintain SME status now that we are taking the step into Europe with registrations in several European countries," says Jonas Jönmark, CEO of AcuCort
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q2-osavuosiraportti
70 päivää sitten‧34 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 14.10.·AcuCort AB: AcuCort strengthens its management team with the appointment of Anna Chérouvrier Hansson as Business Development Director today at 13:00 ∙ Cision AcuCort has appointed Anna Chérouvrier Hansson as its Business Development Director. The appointment is part of AcuCort's continued commercial development and focus on strengthening strategic partnerships to support the launch of Zeqmelit® in additional markets. Anna Chérouvrier Hansson has more than 15 years of experience in business development, sales and marketing within the life science sector. She has held senior positions in both listed companies and fast-growing SMEs, including SenzaGen and Camurus. At SenzaGen, she played a key role in building and driving the company's business development and commercialization strategy, establishing a global network of licensees and distributors, and negotiating international agreements. At Camurus, she was instrumental in launching the company’s first commercial product in supportive cancer care across multiple international markets. “We are very pleased to welcome Anna to AcuCort. Her solid experience in business development, international partnerships and commercialization in life science will be an important addition to our growth journey. Anna’s drive, structured approach and strategic skills make her an excellent fit for our team,” says Jonas Jönmark, CEO of AcuCort. “I am very much looking forward to becoming part of AcuCort and contributing to the company’s continued growth and commercial success,” says Anna Chérouvrier Hansson, newly appointed Business Development Director. For further information, please contact:24.10.·It only applies that everyone who has different medications approves this film as an alternative.. I think it can help you and me as well as those who own shares...2 päivää sitten · Muokattu·Yes, this way of giving medicine is nothing less than revolutionary, and that is why I have them in my portfolio. The big problem is that Jonas Jönmark has refused to sell Zeqmelit to people with cancer and to people with allergies. I still don't understand that he is CEO, all other companies would have let him go a long time ago, already when he made an excuse that there was a year's delay in the launch because there was nonsense with the labels. Just for the record, I have worked in a medical company where I was responsible for the labels, and it has never taken a year to get new ones if there was nonsense with the first batch. If it was because there were problems with the text that had to be approved, then it is also amateurish that this was not cleared and in place. It is four years too late for Anna Chérouvrier Hansson to be hired, she should have been there from the start, so that there were no logistics problems. The CEO is a liability at AcuCort and therefore he must be replaced with someone who has experience in sales and management.
- 8.10. · Muokattu·Strange and unfortunate that this has not been shared here on Shareville. I can see that it has been viewed 66 times. English is spoken and there are no texts that can translate the presentation. Acucort presentation September 24, 2025 https://vimeo.com/1121626529?&login=true#_=_8.10.·I was at the conference - and it was a really good presentation - and bought it afterwards. But yes - I did some research - and among professionals there is great enthusiasm for the product and there is a really good dialogue that way - but the company seems to have big challenges with communication even with the end users!? I have written to the CEO to find out when and how we will see an intensified effort aimed at the users!?
- 27.9.·I didn't know about AcuCort until I heard them at the weekly LifeSciences conference 24/9'2025 - it sounded so exciting that during the presentation I took a small position of 20,000 shares at 0.55 - and then thought that I would take a closer look at it, and then possibly add to it along the way in their commercialization journey. And then I had a chat with ChatGPT about the case - and 16 pages came out of it, which I have as a pdf in my FB Group "Dividend & Risk Stocks_Balanced Portfolio", if anyone is interested.
- 25.9.·Acucort receives SME status extension from EMA Life science company Acucort has received an extension of its SME status (small or medium-sized enterprises) from the European Medicines Agency (EMA) until the end of 2026, according to a press release. The extension means that the company will be fully or partially exempt from fees in connection with regulatory applications related to the sale and marketing of medicines within the EU and EEA. "It is of key importance to maintain SME status now that we are taking the step into Europe with registrations in several European countries," says Jonas Jönmark, CEO of AcuCort
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market SE
Määrä
Osto
3 790
Myynti
Määrä
7 950
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 000 | SWB | NON | ||
| 7 000 | SWB | AVA | ||
| 12 353 | NON | AVA | ||
| 6 010 | NON | AVA | ||
| 3 187 | NON | AVA |
Ylin
0,628VWAP
Alin
0,597VaihtoMäärä
0,1 85 914
VWAP
Ylin
0,628Alin
0,597VaihtoMäärä
0,1 85 914
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordnet Bank AB | 44 766 | 26 511 | +18 255 | 18 411 |
| Swedbank AB | 15 100 | 0 | +15 100 | 0 |
| Carnegie Investment Bank AB | 6 205 | 0 | +6 205 | 0 |
| Nordea Bank Abp | 870 | 0 | +870 | 0 |
| Skandinaviska Enskilda Banken AB | 39 | 0 | +39 | 0 |
| SSW Market Making GmbH | 0 | 3 640 | −3 640 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Avanza Bank AB | 18 934 | 55 763 | −36 829 | 18 640 |
| SSW Market Making GmbH | 0 | 3 640 | −3 640 | 0 |
| Skandinaviska Enskilda Banken AB | 39 | 0 | +39 | 0 |
| Nordea Bank Abp | 870 | 0 | +870 | 0 |
| Carnegie Investment Bank AB | 6 205 | 0 | +6 205 | 0 |
| Swedbank AB | 15 100 | 0 | +15 100 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 14.11. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 19.8. | |
| 2024 Yhtiökokous | 12.5. | |
| 2025 Q1-osavuosiraportti | 8.5. | |
| 2024 Q4-osavuosiraportti | 21.2. | |
| Merkintäoikeusanti | 3.1. |
Datan lähde: Millistream, Quartr
Q2-osavuosiraportti
70 päivää sitten‧34 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 14.11. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 19.8. | |
| 2024 Yhtiökokous | 12.5. | |
| 2025 Q1-osavuosiraportti | 8.5. | |
| 2024 Q4-osavuosiraportti | 21.2. | |
| Merkintäoikeusanti | 3.1. |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 14.10.·AcuCort AB: AcuCort strengthens its management team with the appointment of Anna Chérouvrier Hansson as Business Development Director today at 13:00 ∙ Cision AcuCort has appointed Anna Chérouvrier Hansson as its Business Development Director. The appointment is part of AcuCort's continued commercial development and focus on strengthening strategic partnerships to support the launch of Zeqmelit® in additional markets. Anna Chérouvrier Hansson has more than 15 years of experience in business development, sales and marketing within the life science sector. She has held senior positions in both listed companies and fast-growing SMEs, including SenzaGen and Camurus. At SenzaGen, she played a key role in building and driving the company's business development and commercialization strategy, establishing a global network of licensees and distributors, and negotiating international agreements. At Camurus, she was instrumental in launching the company’s first commercial product in supportive cancer care across multiple international markets. “We are very pleased to welcome Anna to AcuCort. Her solid experience in business development, international partnerships and commercialization in life science will be an important addition to our growth journey. Anna’s drive, structured approach and strategic skills make her an excellent fit for our team,” says Jonas Jönmark, CEO of AcuCort. “I am very much looking forward to becoming part of AcuCort and contributing to the company’s continued growth and commercial success,” says Anna Chérouvrier Hansson, newly appointed Business Development Director. For further information, please contact:24.10.·It only applies that everyone who has different medications approves this film as an alternative.. I think it can help you and me as well as those who own shares...2 päivää sitten · Muokattu·Yes, this way of giving medicine is nothing less than revolutionary, and that is why I have them in my portfolio. The big problem is that Jonas Jönmark has refused to sell Zeqmelit to people with cancer and to people with allergies. I still don't understand that he is CEO, all other companies would have let him go a long time ago, already when he made an excuse that there was a year's delay in the launch because there was nonsense with the labels. Just for the record, I have worked in a medical company where I was responsible for the labels, and it has never taken a year to get new ones if there was nonsense with the first batch. If it was because there were problems with the text that had to be approved, then it is also amateurish that this was not cleared and in place. It is four years too late for Anna Chérouvrier Hansson to be hired, she should have been there from the start, so that there were no logistics problems. The CEO is a liability at AcuCort and therefore he must be replaced with someone who has experience in sales and management.
- 8.10. · Muokattu·Strange and unfortunate that this has not been shared here on Shareville. I can see that it has been viewed 66 times. English is spoken and there are no texts that can translate the presentation. Acucort presentation September 24, 2025 https://vimeo.com/1121626529?&login=true#_=_8.10.·I was at the conference - and it was a really good presentation - and bought it afterwards. But yes - I did some research - and among professionals there is great enthusiasm for the product and there is a really good dialogue that way - but the company seems to have big challenges with communication even with the end users!? I have written to the CEO to find out when and how we will see an intensified effort aimed at the users!?
- 27.9.·I didn't know about AcuCort until I heard them at the weekly LifeSciences conference 24/9'2025 - it sounded so exciting that during the presentation I took a small position of 20,000 shares at 0.55 - and then thought that I would take a closer look at it, and then possibly add to it along the way in their commercialization journey. And then I had a chat with ChatGPT about the case - and 16 pages came out of it, which I have as a pdf in my FB Group "Dividend & Risk Stocks_Balanced Portfolio", if anyone is interested.
- 25.9.·Acucort receives SME status extension from EMA Life science company Acucort has received an extension of its SME status (small or medium-sized enterprises) from the European Medicines Agency (EMA) until the end of 2026, according to a press release. The extension means that the company will be fully or partially exempt from fees in connection with regulatory applications related to the sale and marketing of medicines within the EU and EEA. "It is of key importance to maintain SME status now that we are taking the step into Europe with registrations in several European countries," says Jonas Jönmark, CEO of AcuCort
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market SE
Määrä
Osto
3 790
Myynti
Määrä
7 950
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 000 | SWB | NON | ||
| 7 000 | SWB | AVA | ||
| 12 353 | NON | AVA | ||
| 6 010 | NON | AVA | ||
| 3 187 | NON | AVA |
Ylin
0,628VWAP
Alin
0,597VaihtoMäärä
0,1 85 914
VWAP
Ylin
0,628Alin
0,597VaihtoMäärä
0,1 85 914
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordnet Bank AB | 44 766 | 26 511 | +18 255 | 18 411 |
| Swedbank AB | 15 100 | 0 | +15 100 | 0 |
| Carnegie Investment Bank AB | 6 205 | 0 | +6 205 | 0 |
| Nordea Bank Abp | 870 | 0 | +870 | 0 |
| Skandinaviska Enskilda Banken AB | 39 | 0 | +39 | 0 |
| SSW Market Making GmbH | 0 | 3 640 | −3 640 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Avanza Bank AB | 18 934 | 55 763 | −36 829 | 18 640 |
| SSW Market Making GmbH | 0 | 3 640 | −3 640 | 0 |
| Skandinaviska Enskilda Banken AB | 39 | 0 | +39 | 0 |
| Nordea Bank Abp | 870 | 0 | +870 | 0 |
| Carnegie Investment Bank AB | 6 205 | 0 | +6 205 | 0 |
| Swedbank AB | 15 100 | 0 | +15 100 | 0 |